Delivery of glucose-6-phosphatase in a canine model for glycogen storage disease, type Ia, with adeno-associated virus (AAV) vectors
- 9 July 2002
- journal article
- research article
- Published by Springer Nature in Gene Therapy
- Vol. 9 (15) , 1015-1022
- https://doi.org/10.1038/sj.gt.3301728
Abstract
No abstract availableKeywords
This publication has 31 references indexed in Scilit:
- Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vectorNature Genetics, 2000
- Sustained correction of bleeding disorder in hemophilia B mice by gene therapyProceedings of the National Academy of Sciences, 1999
- Long-term correction of canine hemophilia B by gene transfer of blood coagulation factor IX mediated by adeno-associated viral vectorNature Medicine, 1999
- Correction of hemophilia B in canine and murine models using recombinant adeno-associated viral vectorsNature Medicine, 1999
- Adeno-Associated Viral Vector-Mediated Gene Transfer of Human Blood Coagulation Factor IX Into Mouse LiverBlood, 1998
- Persistent and therapeutic concentrations of human factor IX in mice after hepatic gene transfer of recombinant AAV vectorsNature Genetics, 1997
- Stable gene transfer and expression of human blood coagulation factor IX after intramuscular injection of recombinant adeno-associated virusProceedings of the National Academy of Sciences, 1997
- Recombinant adeno-associated virus for muscle directed gene therapyNature Medicine, 1997
- Persistent expression of human clotting factor IX from mouse liver after intravenous injection of adeno-associated virus vectorsProceedings of the National Academy of Sciences, 1997
- Gene delivery to skeletal muscle results in sustained expression and systemic delivery of a therapeutic proteinProceedings of the National Academy of Sciences, 1996